Sulindac

Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer[1][2].

Product Specifications

CAS Number

[38194-50-2]

Product Name Alternative

MK-231

UNSPSC

12352005

Hazard Statement

H301, H317, H334, H361

Target

NF-κB; PD-1/PD-L1

Type

Reference compound

Related Pathways

Immunology/Inflammation; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Sulindac.html

Purity

99.68

Solubility

DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL

Smiles

O=C(CC(C1=C2C=CC(F)=C1)=C(/C2=C/C3=CC=C(C=C3)S(C)=O)C)O

Molecular Formula

C20H17FO3S

Molecular Weight

356.41

Precautions

H301, H317, H334, H361

References & Citations

[1]Byong-Ki Cha, et al. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget. 2016 Aug 30;7 (35) :57213-57227. |[2]Bin Yi, et al. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy. Mol Cancer Ther. 2021 Jul;20 (7) :1295-1304.